Donor immune cells deployed in fight against tough childhood and adult cancers

NCT ID NCT05238792

Recruiting now Disease control Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety of a new cell therapy for people with high-risk solid tumors that have come back or not responded to standard treatments. Doctors are giving patients specially trained immune cells (T cells) from healthy donors that are designed to recognize and attack multiple cancer proteins. The study will enroll both children (ages 6-17) and adults (ages 18-70) to find the safest dose of these cells, which may be given with or without a short course of chemotherapy first.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR